Bio-Rad Laboratories has announced FDA clearance of two multiplex infectious-disease serology panels for use on the Bioplex 2200 system.
These are the Bioplex ToRC IgG panel and the Bioplex HSV-1 and HSV-2 IgG panel.
The Bioplex 2200 system is a fully automated random-access platform that employs multiplexing technology to analyse multiple disease markers from a single patient-sample.
The ToRC IgG kit simultaneously detects IgG class antibodies to Toxoplasma gondii, rubella and cytomegalovirus (CMV).
Toxoplasma gondii, rubella and CMV can cause a variety of serious conditions in an unborn foetus, including blindness, brain damage and death.
The HSV-1 and HSV-2 IgG kit utilises type-specific proteins to simultaneously detect and differentiate IgG class antibodies to the two most common herpes subtypes, HSV-1 and HSV-2.
The ToRC IgG kit is available for sale and the HSV will soon also be available.
The Bioplex 2200 system is a fully-automated random-access multiplex testing system.
It allows clinical laboratories to rapidly process or 'multiplex' multiple individual tests that are traditionally processed separately using a single small-volume patient sample.
